Ana Beloqui

List of Publications by Year
in descending order

35 papers	2,302 citations	257101 24 h-index	360668 35 g-index
35 all docs	35 docs citations	35 times ranked	3131 citing authors

#	Article	IF	Citations
1	Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 143-161.	1.7	488
2	pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease. International Journal of Pharmaceutics, 2014, 473, 203-212.	2.6	196
3	Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. Journal of Controlled Release, 2013, 166, 115-123.	4.8	176
4	Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine DSS-induced colitis. International Journal of Pharmaceutics, 2013, 454, 775-783.	2.6	115
5	Overcoming the intestinal barrier: A look into targeting approaches for improved oral drug delivery systems. Journal of Controlled Release, 2020, 322, 486-508.	4.8	106
6	Mechanisms of transport of polymeric and lipidic nanoparticles across the intestinal barrier. Advanced Drug Delivery Reviews, 2016, 106, 242-255.	6.6	98
7	Self-Nano-Emulsifying Drug-Delivery Systems: From the Development to the Current Applications and Challenges in Oral Drug Delivery. Pharmaceutics, 2020, 12, 1194.	2.0	86
8	Nanoparticle transport across in vitro olfactory cell monolayers. International Journal of Pharmaceutics, 2016, 499, 81-89.	2.6	81
9	A comparative study of curcumin-loaded lipid-based nanocarriers in the treatment of inflammatory bowel disease. Colloids and Surfaces B: Biointerfaces, 2016, 143, 327-335.	2.5	76
10	Dextranâ€“protamine coated nanostructured lipid carriers as mucus-penetrating nanoparticles for lipophilic drugs. International Journal of Pharmaceutics, 2014, 468, 105-111.	2.6	72
11	An overview of in vitro, ex vivo and in vivo models for studying the transport of drugs across intestinal barriers. Advanced Drug Delivery Reviews, 2021, 175, 113795.	6.6	69
12	A human intestinal M-cell-like model for investigating particle, antigen and microorganism translocation. Nature Protocols, 2017, 12, 1387-1399.	5.5	64
13	Nanostructured lipid carriers as oral delivery systems for poorly soluble drugs. Journal of Drug Delivery Science and Technology, 2017, 42, 144-154.	1.4	62
14	Biodistribution of Nanostructured Lipid Carriers (NLCs) after intravenous administration to rats: Influence of technological factors. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 84, 309-314.	2.0	51
15	Surface Modification of Lipid-Based Nanoparticles. ACS Nano, 2022, 16, 7168-7196.	7.3	49
16	Fate of nanostructured lipid carriers (NLCs) following the oral route: design, pharmacokinetics and biodistribution. Journal of Microencapsulation, 2014, 31, 1-8.	1.2	47
17	The interaction of protamine nanocapsules with the intestinal epithelium: A mechanistic approach. Journal of Controlled Release, 2016, 243, 109-120.	4.8	45
18	Reformulating cyclosporine A (CsA): More than just a life cycle management strategy. Journal of Controlled Release, 2016, 225, 269-282.	4.8	45

#	Article	IF	Citations
19	Novel strategy for oral peptide delivery in incretin-based diabetes treatment. Gut, 2020, 69, 911-919.	6.1	41
20	Oral delivery of oleuropein-loaded lipid nanocarriers alleviates inflammation and oxidative stress in acute colitis. International Journal of Pharmaceutics, 2020, 586, 119515.	2.6	40
21	The stimulation of GLP-1 secretion and delivery of GLP-1 agonists via nanostructured lipid carriers. Nanoscale, 2018, 10, 603-613.	2.8	35
22	Targeted nanoparticles towards increased L cell stimulation as a strategy to improve oral peptide delivery in incretin-based diabetes treatment. Biomaterials, 2020, 255, 120209.	5.7	30
23	Advances in lipid carriers for drug delivery to the gastrointestinal tract. Current Opinion in Colloid and Interface Science, 2021, 52, 101414.	3.4	27
24	Cyclosporine A-loaded lipid nanoparticles in inflammatory bowel disease. International Journal of Pharmaceutics, 2016, 503, 196-198.	2.6	26
25	Design and evaluation of self-nanoemulsifying drug delivery systems (SNEDDSs) for senicapoc. International Journal of Pharmaceutics, 2020, 580, 119180.	2.6	25
26	A Mechanistic Study on Nanoparticle-Mediated Glucagon-Like Peptide-1 (GLP-1) Secretion from Enteroendocrine L Cells. Molecular Pharmaceutics, 2016, 13, 4222-4230.	2.3	24
27	Size Effect on Lipid Nanocapsule-Mediated GLP-1 Secretion from Enteroendocrine L Cells. Molecular Pharmaceutics, 2018, 15, 108-115.	2.3	23
28	Delivery of Peptides Via the Oral Route: Diabetes Treatment by Peptide-Loaded Nanoparticles. Current Pharmaceutical Design, 2016, 22, 1161-1176.	0.9	19
29	Oral Delivery of Biologics in Inflammatory Bowel Disease Treatment. Frontiers in Bioengineering and Biotechnology, 2021, 9, 675194.	2.0	18
30	Solvent-free protamine nanocapsules as carriers for mucosal delivery of therapeutics. European Polymer Journal, 2017, 93, 695-705.	2.6	17
31	Impact of PEGylation on an antibody-loaded nanoparticle-based drug delivery system for the treatment of inflammatory bowel disease. Acta Biomaterialia, 2022, 140, 561-572.	4.1	13
32	Targeting Inflammatory Bowel Diseases by Nanocarriers Loaded with Small and Biopharmaceutical Anti-Inflammatory Drugs. Current Pharmaceutical Design, 2016, 22, 6192-6206.	0.9	12
33	Ascorbyl-dipalmitate-stabilised nanoemulsions as a potential localised treatment of inflammatory bowel diseases. International Journal of Pharmaceutics, 2020, 586, 119533.	2.6	10
34	Solid lipid nanocarriers diffuse effectively through mucus and enter intestinal cells â€“ but where is my peptide?. International Journal of Pharmaceutics, 2020, 586, 119581.	2.6	9
35	Quality-by-Design-Based Development of a Voxelotor Self-Nanoemulsifying Drug-Delivery System with Improved Biopharmaceutical Attributes. Pharmaceutics, 2021, 13, 1388.	2.0	7